Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

Go to full paper published in the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.